Copper peptide hair serums are sold with confident timelines and a comparison to minoxidil. Search results for the question are unusually poor: forum threads from more than a decade ago, a few clinic blogs, and pages that repeat the same claims without naming a study. This page does the one thing none of them does — it counts every indexed record on copper peptides and hair, opens each human study, and says what was actually given to whom. Our peptides for hair growth hub places copper peptides beside every other hair peptide; this page is the full census for one ingredient. It is not advice to use or avoid any product.
What "copper peptide" means on a hair label
Two different molecules are sold under the name:
- GHK-Cu — glycyl-histidyl-lysine bound to copper. Its ingredient-list (INCI) name is copper tripeptide-1. This is the copper peptide in most serums, including the skin products covered on our copper peptides page.
- AHK-Cu — alanyl-histidyl-lysine bound to copper. It differs from GHK by one amino acid (alanine instead of glycine), and it is the molecule used in the most-cited hair-follicle laboratory study. Our AHK-Cu entry counts its record separately.
Searches in this census used every name: copper tripeptide-1, GHK-Cu, glycyl-histidyl-lysine and "copper peptide". PubMed reported that it could not match the phrases "prezatide copper" and "GHK copper", so those two names contributed nothing; the other names did.
The census
A PubMed search on 30 September 2026 for those names together with hair, alopecia or follicle returned 18 records. Read one by one:
| Class | Records | What they are |
|---|---|---|
| Not about hair | 3 | Thyroid-follicle biology papers (1990, 1994 ×2) that matched "follicle" |
| Reviews and company papers | 6 | Four by Loren Pickart (2008, 2014, 2015, 2017), whose 2008 review lists Skin Biology, a company selling GHK-Cu products, as his affiliation; and two 2026 reviews of GHK-Cu chemistry and microneedle delivery |
| Laboratory, animal or formulation | 4 | A 2012 stem-cell study of copper-free GHK, a 2020 cell and animal study of a growth-factor formulation, a 2024 delivery-chemistry paper and a 2026 zebrafish inflammation study |
| Human studies | 5 | Described below — every one a mixture |
Restricting the same search to the randomized-controlled-trial publication type returned 0. The filter itself works: minoxidil with alopecia returned 149 in the same session. The retracted-publication filter returned 0. ClinicalTrials.gov returned no registered hair study of GHK-Cu, copper tripeptide or AHK-Cu; its three GHK-Cu registrations are a wound-healing gel, a facial treatment and a blood-level study, against 105 registrations for minoxidil in alopecia.
The five human studies, and what else was in each one
| Study | People | Design | What was given | Could the copper peptide's effect be isolated? |
|---|---|---|---|---|
| Lee 2016, Annals of Dermatology | 45 men with pattern hair loss | Randomized, placebo-controlled, six months (not tagged as an RCT in PubMed) | Copper-free GHK with 5-aminolevulinic acid, two strengths | No — no copper, and a second active |
| Kapoor 2018, J Cosmet Laser Ther | 1,000 patients | Open-label, single arm, no control group | Scalp injections of VEGF, basic FGF, IGF, KGF, thymosin beta-4 and copper tripeptide-1, eight sessions | No — six actives, no comparison group |
| Bertin 2018, J Cosmet Laser Ther | 4 cases | Case series | Fractional laser, then topical finasteride 0.05% with growth factors and copper peptide 1% | No — finasteride is an approved hair-loss drug |
| Patel 2024, Cureus | Adults with dandruff | Open-label, 15 days, no control | A hydroxy-acid scrub, then a serum with copper tripeptide-1, witch hazel, hesperidin, hyaluronic acid and pea protein | No — and the study declares that one author is employed by the product's manufacturer |
| Kuceki 2025, JAAD International | 7 men | Retrospective, blinded photo review | Scalp "tattooing" of 0.5% minoxidil, 0.1% dutasteride and 1.2% copper peptides, five monthly sessions, plus topical minoxidil at home | No — two established hair-loss drugs in the same solution |
The pattern is the finding. In every human study on record, the copper peptide arrived alongside something else, and in three of them that something was an approved or widely used hair-loss drug (finasteride, dutasteride, minoxidil). The results of those studies may be real; they cannot be credited to the copper peptide.
The older laboratory and animal work, dated
The three studies that most copper-peptide hair pages cite do not appear in the 18, because none uses the names above. A second search for the older terms (Folligen, PC1031, copper-binding peptide, peptide copper complexes — PubMed does not recognise the brand name Tricomin at all) returned the first two; the third is indexed under AHK-Cu's chemical name.
- 1991 — a conference abstract on "peptide copper complexes" in C3H mice (Trachy 1991). Its authors, including Loren Pickart and Hideo Uno, are listed at ProCyte Corporation, the company then developing copper peptides.
- 1993 — Uno and Kurata reported that a copper-binding peptide enlarged follicles in fuzzy rats, "similar to that of topical minoxidil." This is the earliest traceable source of the minoxidil comparison, and it is a rat experiment.
- 2007 — Pyo and colleagues at Seoul National University found that AHK-Cu at 10⁻¹² to 10⁻⁹ M lengthened human hair follicles in a dish and increased dermal papilla cell growth; the fall in cell death was not statistically significant. It is the most cited hair study in copper-peptide marketing, and it did not test GHK-Cu.
The commercial history that forum threads from the 2000s refer to — copper-peptide hair products sold from the 1990s onward — sits in company literature rather than in the indexed record, and this census could not date it from a primary source.
"Works like minoxidil" and "blocks DHT"
Two claims recur on the pages that rank for this question. Neither survives the census.
The minoxidil comparison. The only indexed source for it is the 1993 rat study quoted above. No study has compared a copper peptide with minoxidil in people. Minoxidil is an FDA-approved drug for pattern hair loss; the benchmark section of our hair growth hub sets out its standing and finasteride's.
The DHT claim. Only one of the 18 records mentions dihydrotestosterone or 5-alpha reductase, and it does so because the treatment in that study (Bertin 2018) also contained finasteride, which is a DHT blocker. There is no indexed human study showing that a copper peptide lowers DHT or blocks the enzyme that makes it.
What no study has tested
- A copper peptide alone, against a placebo, on human scalp hair.
- Whether GHK-Cu crosses intact human scalp skin in meaningful amounts; the delivery studies in the census use microneedles, lasers, tattoo machines or injection to get past the barrier.
- GHK-Cu combined with minoxidil against minoxidil alone — the design that would answer whether adding it changes anything.
- Any difference between men and women; the only controlled trial enrolled men, and it used copper-free GHK. Our pages on hair peptides for women and for men cover the sex-specific evidence for other ingredients.
For readers comparing copper peptides with other hair-serum ingredients, the two peptides with small human trials of their own are biotinoyl tripeptide-1 and acetyl tetrapeptide-3. Shedding or thinning that is new or rapid is a reason to see a dermatologist, who can identify the cause before any product is chosen.
Sources
- PubMed via NCBI E-utilities, searches run 2026-09-30, each checked for unmatched phrases (
quotedphrasesnotfound): copper-peptide names × hair/alopecia/follicle (18); with"randomized controlled trial"[pt](0); control minoxidil × alopecia × RCT (149);"Retracted Publication"[pt](0); with DHT/5-alpha reductase (1). - ClinicalTrials.gov API v2, queries "GHK-Cu" (3), "copper tripeptide" (0), "AHK-Cu" (0), minoxidil × alopecia (105), run 2026-09-30.
- Lee WJ, et al. Efficacy of a Complex of 5-Aminolevulinic Acid and Glycyl-Histidyl-Lysine Peptide on Hair Growth. Ann Dermatol 2016 — PMID 27489425.
- Kapoor R, Shome D. Intradermal injections of a hair growth factor formulation for enhancement of human hair regrowth. J Cosmet Laser Ther 2018;20(6):369-379 — PMID 29482481.
- Bertin ACJ, et al. Fractional non-ablative laser-assisted drug delivery leads to improvement in male and female pattern hair loss. J Cosmet Laser Ther 2018;20(7-8):391-394 — PMID 29452017.
- Patel MN, et al. A Novel Scalp Treatment Regimen Combining a Hydroxy Acid-Based Scrub and Copper Tripeptide Serum in the Management of Seborrheic Dermatitis in Adults. Cureus 2024;16(9):e70108 — PMID 39449909.
- Kuceki G, et al. Enhanced hair regrowth with five monthly sessions of minoxidil-dutasteride-copper peptides tattooing for androgenetic alopecia. JAAD Int 2025;20:38-40 — PMID 40225275, full text via PMC11992372.
- Trachy RE, Fors TD, Pickart L, Uno H. The hair follicle-stimulating properties of peptide copper complexes. Results in C3H mice. Ann N Y Acad Sci 1991;642:468-9 — PMID 1809108.
- Uno H, Kurata S. Chemical agents and peptides affect hair growth. J Invest Dermatol 1993 — PMID 8326148.
- Pyo HK, et al. The effect of tripeptide-copper complex on human hair growth in vitro. Arch Pharm Res 2007;30(7):834-9 — PMID 17703734.